Treating Oral Yeast Infection

Study: Once-Daily Tablet as Effective as Multiple Pill Dosings for Treating Oral Yeast Infection in HIV/AIDS Patients

DETROIT - A once-daily medication option for treating the most common mouth infection in HIV/AIDS patients has shown to be just as effective and safe as taking an anti-fungal pill five times a day, according to a Henry Ford Hospital study.

Researchers found that a small tablet applied daily that sticks to the gum and dissolves inside the mouth with few or no side effects is a novel, convenient option for treating an infection called oral candidiasis (OC), which occurs in about one third to one half of HIV patients and up to 90 percent of AIDS patients.

The study is believed to be the largest to date involving HIV/AIDS patients with OC. The infection is also common in patients suffering from many forms of cancer, especially those with head and neck cancer, in which the infection rate is as high 77 percent.

The study is being presented at the 49th annual Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco.

"This is an exciting new, convenient way for treating this infection," says Jose A. Vazquez, M.D., the study's lead author and a Henry Ford Infectious Disease physician.

"It's a tablet that you just stick on the gum and it releases an anti-fungal agent over the course of six to eight hours. Because the anti-fungal agent stays in the mouth, it provides the same relief as the oral medication but with few or no side effects."

Dr. Vazquez says medication taken orally or by injection often is absorbed into other parts of the body, thus causing side effects for patients such as nausea, vomiting, diarrhea and liver dysfunction.

The study compared the effectiveness and safety of taking 50 milligrams of a miconazole mucoadhesive buccal tablet once-daily to 10 milligrams of clotrimazole, a common anti-fungal pill five times a day. Of the 578 patients enrolled in the randomized study, 291 received the tablet and 287 received the clotrimazole pill.

SOURCE:http://henryford.com

For information regarding Prostate Cancer, Robotic Prostatectomy, Other Robotic Procedures, Vattikuti Urology Institute visit www.drmanimenon.com

The Vattikuti Urology Institute

K9, 2799 W. Grand Blvd.

Detroit MI 48202

2010 IRUS

On behalf of the Vattikuti Urology Institute and Henry Ford Hospital, it is my great pleasure to invite you to participate in our 2010 International Robotic Urology Symposium. Our theme of "Advance" continues, looking to the future with improved technique development.

Our stimulating scientific program will feature numerous live 3-D operative demonstrations, as well as critique panels covering the foremost topics in robotic urology.

We are very excited to showcase the critique panels format in January. The world's leaders in robotic surgery will debate the advantages and disadvantages of techniques and share competing views on numerous topics, which will also invite registrant participation.

Our program will be held at the magnificent Wynn Las Vegas and will include an opportunity to see the acclaimed show Le Rêve.

I look forward to seeing you at the Wynn Las Vegas!


Mani Menon, M.D., FACS
The Raj and Padma Vattikuti Distinguished Chair
Director, Vattikuti Urology Institute
Henry Ford Health System

Facts about Influenza(H1N1 Virus)

According to the Center for Disease Control and Prevention (CDC) Millions of people in the United States - about 5% to 20% of U.S. residents - will get influenza each year.

Also according to the CDC, an average of about 36,000 people per year in the United States die from influenza-related causes, and more than 200,000 have to be admitted to the hospital as a result of influenza-related causes.

People age 65 years and older, people of any age with chronic medical conditions (such as asthma, diabetes, or heart disease), pregnant women, and young children are at higher risk for complications from seasonal influenza. However, for reasons we don't know yet, H1N1 has affected younger people (under 25) more so than older people. So far, people older than 64 do not appear to be at increased risk of H1N1.

Pneumonia, bronchitis, and sinus and ear infections are three examples of complications from flu.

The symptoms of H1N1 in people are similar to the symptoms of seasonal flu and include fever, cough, sore throat, body aches, headache, chills and fatigue. Some people have reported diarrhea and vomiting associated with swine flu. Severe illnesses and death has occurred as a result of illness associated with this virus.

H1N1 and seasonal flu are similar in many ways in terms of how they spread, their signs, symptoms and severity.

The CDC is testing a vaccine specific to H1N1 and is expected to be ready for public use sometime this fall. This vaccine is not intended to replace the annual seasonal flu vaccine, however. And unlike the seasonal flu vaccine, the H1N1 vaccine will be given in two doses about 30 days apart.

The CDC recommends the following groups receive the H1N1 vaccine as well as those who were previously diagnosed with H1N1:

-- Pregnant women.
-- Caregivers of children younger than 6 months of age.
-- Health care workers and Emergency Medical Service personnel.
-- People 6 months to 24 years of age.
-- People aged 25 to 64 who have a health condition associated with a higher risk of medical complications from the flu.

SOURCE: Centers for Disease Control and Prevention Web site, www.cdc.gov

For more information about the H1N1 virus, visit http://henryford.com/swineflu

For information regarding Prostate Cancer, Robotic Prostatectomy, Other Robotic Procedures, Vattikuti Urology Institute visit www.drmanimenon.com

Nerve-Sparing Technique Proves To Be Better

The Veil of Aphrodite results in significantly better erectile function outcomes.

Surgeons at the Vattikuti Urology Institute pioneered a new technique of nerve-sparing robotic prostatectomy. The "Veil of Aphrodite" results in significantly better erectile function outcomes than for patients who receive conventional nerve-sparing surgery, and without compromising cancer control.

Best-Published Erectile Function Outcomes
Sexual function was assessed a year following surgery by a questionnaire of men with no pre-existing erectile dysfunction who underwent robotic radical prostatectomy incorporating the Veil of Aphrodite. Depending on your pre-existing erectile dysfunction, you may or may not achieve similar results.

	Veil of Aphrodite nerve-sparing	Conventional nerve-sparing
Men had erections strong enough for intercourse	97 percent	74 percent
Men had erections that were normal	85 percent	26 percent
Men had normal erections without medications	51 percent	17 percent

The radar graph shows pre-operative and post-operative scores in each patient and the ability of the procedure to preserve sexual function. The blue areas represent the measured loss of erectile function after surgery. The smaller the blue area, the better the outcome. Patients who had the Veil of Aphrodite did better than patients who had a conventional nerve-sparing procedure.

The technique of the operation and the results of the year-long study were published in numerous medical journals. The potency outcomes are the highest reported to date. These results should help ease men's concern as to the future of their sex lives when faced with a radical prostatectomy, the surgical removal of the prostate and surrounding tissue.